ARWR

SEC source: 0001242615-26-000002 · wk-form4_1787261143.xml · nonDerivative · entry 1

OLUKOTUN ADEOYE Y · CIK 0001242615 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,600

F1 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

SEC source: 0001250379-26-000002 · wk-form4_1787260939.xml · nonDerivative · entry 1

PERRY MICHAEL S · CIK 0001250379 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 111,459

F1 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $87.20 to $87.44, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

SEC source: 0002141314-26-000004 · wk-form4_1781747052.xml · nonDerivative · entry 1

Cohen Matthew Gregory · CIK 0002141314 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,882

F1 · shares: Represents shares underlying restricted stock units with a grant date 06/15/2026, which will vest over three years.

SEC source: 0001767584-26-000002 · wk-form4_1778799941.xml · nonDerivative · entry 1

Lu Hongbo · CIK 0001767584 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 52,012

F1 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

SEC source: 0001830755-26-000007 · wk-form4_1777070312.xml · nonDerivative · entry 1

Hamilton James C · CIK 0001830755 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 226,958

F1 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F2 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.13, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

F3 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

SEC source: 0000879407-26-000039 · wk-form4_1777070680.xml · nonDerivative · entry 3

Apel Daniel Joseph · CIK 0002081169 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 162,905

F1 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F2 · shares: Partial disposition of shares to satisfy tax withholding obligations.

F6 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $71.55 to $71.97, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

F4 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

SEC source: 0000879407-26-000039 · wk-form4_1777070680.xml · nonDerivative · entry 2

Apel Daniel Joseph · CIK 0002081169 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 171,635

F1 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F2 · shares: Partial disposition of shares to satisfy tax withholding obligations.

F5 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $70.29 to $70.51, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

F4 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

SEC source: 0000879407-26-000039 · wk-form4_1777070680.xml · nonDerivative · entry 1

Apel Daniel Joseph · CIK 0002081169 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 172,792

F1 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F2 · shares: Partial disposition of shares to satisfy tax withholding obligations.

F3 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $69.50 to $70.23, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

F4 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

SEC source: 0001830755-26-000006 · wk-form4_1773097203.xml · nonDerivative · entry 1

Hamilton James C · CIK 0001830755 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 236,958

F1 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F2 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $63.80 to $64.51, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

F3 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

SEC source: 0001830755-26-000004 · wk-form4_1767915953.xml · nonDerivative · entry 1

Hamilton James C · CIK 0001830755 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 246,958

F1 · shares: Represents shares underlying restricted stock units which will vest in four equal annual installments.

F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

SEC source: 0002081169-26-000002 · wk-form4_1767915947.xml · nonDerivative · entry 1

Apel Daniel Joseph · CIK 0002081169 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 176,200

F1 · shares: Represents shares underlying restricted stock units which will vest in four equal annual installments.

F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

SEC source: 0001627183-26-000003 · wk-form4_1767915940.xml · nonDerivative · entry 6

O'Brien Patrick · CIK 0001627183 · COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 547,408

F3 · shares: Represents shares underlying restricted stock units which will vest in four equal annual installments.

F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

SEC source: 0001627183-26-000003 · wk-form4_1767915940.xml · nonDerivative · entry 5

O'Brien Patrick · CIK 0001627183 · COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 472,408

F1 · kind: Gift to relatives

F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

SEC source: 0001627183-26-000003 · wk-form4_1767915940.xml · nonDerivative · entry 4

O'Brien Patrick · CIK 0001627183 · COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 472,848

F1 · kind: Gift to relatives

F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

SEC source: 0001627183-26-000003 · wk-form4_1767915940.xml · nonDerivative · entry 3

O'Brien Patrick · CIK 0001627183 · COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 473,288

F1 · kind: Gift to relatives

F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

SEC source: 0001627183-26-000003 · wk-form4_1767915940.xml · nonDerivative · entry 2

O'Brien Patrick · CIK 0001627183 · COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 473,828

F1 · kind: Gift to relatives

F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

SEC source: 0001627183-26-000003 · wk-form4_1767915940.xml · nonDerivative · entry 1

O'Brien Patrick · CIK 0001627183 · COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 474,368

F1 · kind: Gift to relatives

F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

SEC source: 0001627183-26-000001 · wk-form4_1767667814.xml · nonDerivative · entry 17

O'Brien Patrick · CIK 0001627183 · COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 474,908

F3 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

SEC source: 0001627183-26-000001 · wk-form4_1767667814.xml · nonDerivative · entry 16

O'Brien Patrick · CIK 0001627183 · COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 474,954

F3 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F14 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $63.58 to $64.46, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

SEC source: 0001627183-26-000001 · wk-form4_1767667814.xml · nonDerivative · entry 15

O'Brien Patrick · CIK 0001627183 · COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 477,290

F3 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F13 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $62.54 to $63.39, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

SEC source: 0001627183-26-000001 · wk-form4_1767667814.xml · nonDerivative · entry 14

O'Brien Patrick · CIK 0001627183 · COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 483,163

F3 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F12 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $61.84 to $62.48, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

SEC source: 0001627183-26-000001 · wk-form4_1767667814.xml · nonDerivative · entry 13

O'Brien Patrick · CIK 0001627183 · COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 484,063

F3 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F11 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $60.75 to $61.56, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

SEC source: 0001627183-26-000001 · wk-form4_1767667814.xml · nonDerivative · entry 12

O'Brien Patrick · CIK 0001627183 · COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 484,663

F3 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F4 · shares: Partial disposition of shares to satisfy tax withholding obligations.

F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

SEC source: 0001627183-26-000001 · wk-form4_1767667814.xml · nonDerivative · entry 11

O'Brien Patrick · CIK 0001627183 · COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 484,976

F3 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F4 · shares: Partial disposition of shares to satisfy tax withholding obligations.

F10 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $65.85 to $66.12, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

SEC source: 0001627183-26-000001 · wk-form4_1767667814.xml · nonDerivative · entry 10

O'Brien Patrick · CIK 0001627183 · COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 485,876

F3 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F4 · shares: Partial disposition of shares to satisfy tax withholding obligations.

F9 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $64.36 to $64.70, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

SEC source: 0001627183-26-000001 · wk-form4_1767667814.xml · nonDerivative · entry 9

O'Brien Patrick · CIK 0001627183 · COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 488,576

F3 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F4 · shares: Partial disposition of shares to satisfy tax withholding obligations.

F8 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $63.41 to $64.35, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

SEC source: 0001627183-26-000001 · wk-form4_1767667814.xml · nonDerivative · entry 8

O'Brien Patrick · CIK 0001627183 · COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 500,418

F3 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F4 · shares: Partial disposition of shares to satisfy tax withholding obligations.

F7 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $62.55 to $63.38, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

SEC source: 0001627183-26-000001 · wk-form4_1767667814.xml · nonDerivative · entry 7

O'Brien Patrick · CIK 0001627183 · COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 513,869

F3 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F4 · shares: Partial disposition of shares to satisfy tax withholding obligations.

F6 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $61.66 to $62.54, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

SEC source: 0001627183-26-000001 · wk-form4_1767667814.xml · nonDerivative · entry 6

O'Brien Patrick · CIK 0001627183 · COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 520,033

F3 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F4 · shares: Partial disposition of shares to satisfy tax withholding obligations.

F5 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $60.85 to $61.64, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

SEC source: 0001830755-26-000002 · wk-form4_1767667301.xml · nonDerivative · entry 7

Hamilton James C · CIK 0001830755 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 171,958

F1 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F2 · shares: Partial disposition of shares to satisfy tax withholding obligations.

F4 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

SEC source: 0001830755-26-000002 · wk-form4_1767667301.xml · nonDerivative · entry 6

Hamilton James C · CIK 0001830755 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 172,267

F1 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F2 · shares: Partial disposition of shares to satisfy tax withholding obligations.

F9 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $65.90 to $66.12, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

F4 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

SEC source: 0001830755-26-000002 · wk-form4_1767667301.xml · nonDerivative · entry 5

Hamilton James C · CIK 0001830755 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 172,704

F1 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F2 · shares: Partial disposition of shares to satisfy tax withholding obligations.

F8 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $64.44 to $64.70, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

F4 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

SEC source: 0001830755-26-000002 · wk-form4_1767667301.xml · nonDerivative · entry 4

Hamilton James C · CIK 0001830755 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 173,904

F1 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F2 · shares: Partial disposition of shares to satisfy tax withholding obligations.

F7 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $63.57 to $64.41, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

F4 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

SEC source: 0001830755-26-000002 · wk-form4_1767667301.xml · nonDerivative · entry 3

Hamilton James C · CIK 0001830755 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 186,615

F1 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F2 · shares: Partial disposition of shares to satisfy tax withholding obligations.

F6 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $62.61 to $63.56, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

F4 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

SEC source: 0001830755-26-000002 · wk-form4_1767667301.xml · nonDerivative · entry 2

Hamilton James C · CIK 0001830755 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 201,407

F1 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F2 · shares: Partial disposition of shares to satisfy tax withholding obligations.

F5 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $61.84 to $62.60, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

F4 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

SEC source: 0001830755-26-000002 · wk-form4_1767667301.xml · nonDerivative · entry 1

Hamilton James C · CIK 0001830755 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 207,497

F1 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F2 · shares: Partial disposition of shares to satisfy tax withholding obligations.

F3 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $60.80 to $61.66, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

F4 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

SEC source: 0001423029-26-000001 · wk-form4_1767667178.xml · nonDerivative · entry 2

Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,792,739

F1 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F2 · shares: Partial disposition of shares to satisfy tax withholding obligations.

F5 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $66.21 to $66.58, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

F4 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

SEC source: 0001423029-26-000001 · wk-form4_1767667178.xml · nonDerivative · entry 1

Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,798,510

F1 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F2 · shares: Partial disposition of shares to satisfy tax withholding obligations.

F3 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $65.28 to $66.20, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

F4 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

SEC source: 0001627183-26-000001 · wk-form4_1767667814.xml · nonDerivative · entry 5

O'Brien Patrick · CIK 0001627183 · COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 524,401

F1 · kind: Gift to relatives

F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

SEC source: 0001627183-26-000001 · wk-form4_1767667814.xml · nonDerivative · entry 4

O'Brien Patrick · CIK 0001627183 · COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 524,961

F1 · kind: Gift to relatives

F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

SEC source: 0001627183-26-000001 · wk-form4_1767667814.xml · nonDerivative · entry 3

O'Brien Patrick · CIK 0001627183 · COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 525,521

F1 · kind: Gift to relatives

F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

SEC source: 0001627183-26-000001 · wk-form4_1767667814.xml · nonDerivative · entry 2

O'Brien Patrick · CIK 0001627183 · COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 526,081

F1 · kind: Gift to relatives

F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

SEC source: 0001627183-26-000001 · wk-form4_1767667814.xml · nonDerivative · entry 1

O'Brien Patrick · CIK 0001627183 · COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 526,641

F1 · kind: Gift to relatives

F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

SEC source: 0001423029-25-000009 · wk-form4_1767134792.xml · derivative · entry 6

Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 16,545 shares

Expires 2026-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: All options were fully vested and exercisable as of January 1, 2016.

SEC source: 0001423029-25-000009 · wk-form4_1767134792.xml · derivative · entry 5

Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 16,545

Underlying: Common Stock · 35,181 shares

Expires 2026-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: All options were fully vested and exercisable as of January 1, 2016.

SEC source: 0001423029-25-000009 · wk-form4_1767134792.xml · nonDerivative · entry 4

Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,805,926

F2 · kind: The exercise of non-qualified stock options and sale was made as the stock options were approaching their expiration date. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F4 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $68.10 to $69.08, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

F1 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

SEC source: 0001423029-25-000009 · wk-form4_1767134792.xml · nonDerivative · entry 3

Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,822,471

F2 · kind: The exercise of non-qualified stock options and sale was made as the stock options were approaching their expiration date. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F3 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $69.09 to $69.62, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

F1 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

SEC source: 0001423029-25-000009 · wk-form4_1767134792.xml · nonDerivative · entry 2

Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,857,652

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

SEC source: 0001423029-25-000009 · wk-form4_1767134792.xml · nonDerivative · entry 1

Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,841,107

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

SEC source: 0001506045-25-000007 · wk-form4_1767134785.xml · nonDerivative · entry 1

Ferrari Mauro · CIK 0001506045 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 69,053

F1 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.